Orexigen Therapeutics, Inc. Contracts & Agreements

Debtors Modified Amended Plan of Liquidation (Filed With SEC on May 23, 2019)

Amendment to the Asset Purchase Agreement, dated as of July 26, 2018, by and between Orexigen Therapeutics, Inc. and Nalpropion Pharmaceuticals, Inc (Filed With SEC on July 31, 2018)

Asset Purchase Agreement, dated as of April 23, 2018, by and between Orexigen Therapeutics, Inc. and Nalpropion Pharmaceuticals, Inc. (Schedules and exhibits have been omitted... (Filed With SEC on April 24, 2018)

Key Employee Incentive Plan (Filed With SEC on April 24, 2018)

Instrument of Resignation, Appointment and Acceptance, dated as of March 20, 2018, by and among Orexigen Therapeutics, Inc., Wilmington Savings Fund Society, FSB and U.S. Bank... (Filed With SEC on March 23, 2018)

Debtor in Possession Credit and Security Agreement, dated as of March 12, 2018, by and between the Company, Wilmington Trust, National Association, as administrative agent, and... (Filed With SEC on March 12, 2018)

Form of Exchange Agreement (Filed With SEC on December 1, 2017)

Fourth Amendment to Lease dated October 25, 2016 by and between Orexigen Therapeutics, Inc. and the Regents of the University of California (Filed With SEC on November 14, 2017)

Fifth Amendment to Lease dated September 11, 2017 by and between Orexigen Therapeutics, Inc. and the Regents of the University of California (Filed With SEC on November 14, 2017)

Form of Performance Retention Agreement (Filed With SEC on November 14, 2017)

Amendment No. 3 to Second Amended and Restated Employment Agreement dated October 13, 2017 by and between the Registrant and Michael A. Narachi (Filed With SEC on November 14, 2017)

Amendment No. 3 to Employment Agreement dated October 13, 2017 by and between the Registrant and Thomas Cannell (Filed With SEC on November 14, 2017)

Amendment No. 2 to Employment Agreement dated October 13, 2017 by and between the Registrant and Thomas Lynch (Filed With SEC on November 14, 2017)

Amendment No. 3 to Employment Agreement dated October 13, 2017 by and between the Registrant and Jason Keyes (Filed With SEC on November 14, 2017)

Employment Agreement dated February 23, 2015 by and between the Registrant and Peter Flynn (Filed With SEC on November 14, 2017)

Amendment No. 1 to Employment Agreement dated February 26, 2016 by and between the Registrant and Peter Flynn (Filed With SEC on November 14, 2017)

Amendment No. 2 to Employment Agreement dated June 16, 2016 by and between the Registrant and Peter Flynn (Filed With SEC on November 14, 2017)

Amendment No. 3 to Employment Agreement dated October 13, 2017 by and between the Registrant and Peter Flynn (Filed With SEC on November 14, 2017)

Orexigen Therapeutics, Inc. Shares of Common Stock (par value$0.001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on March 30, 2017)

OREXIGEN THERAPEUTICS, INC. asissuer U.S. BANK NATIONAL ASSOCIATION INDENTURE Dated as ofFebruary 23, 2017 2.75% CONVERTIBLE EXCHANGE SENIOR NOTES DUE 2020 Table of Contents (Filed With SEC on February 24, 2017)

OREXIGEN THERAPEUTICS, INC. asissuer U.S. BANK NATIONAL ASSOCIATION INDENTURE Dated as ofFebruary 23, 2017 2.75% CONVERTIBLE EXCHANGE SENIOR NOTES DUE 2020 Table of Contents (Filed With SEC on February 17, 2017)

SECONDSUPPLEMENTAL INDENTURE (Filed With SEC on February 17, 2017)

FIRST SUPPLEMENTAL INDENTURE (Filed With SEC on December 20, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on August 5, 2016)

OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT FEBRUARY 2, 2016 (Filed With SEC on August 5, 2016)

OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT JUNE 16, 2016 (Filed With SEC on August 5, 2016)

OREXIGEN THERAPEUTICS, INC. AMENDED AND RESTATED 2007 EQUITY INCENTIVE AWARD PLAN ARTICLE 1 PURPOSE (Filed With SEC on August 5, 2016)

OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 2 TO SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT FEBRUARY 4,2016 (Filed With SEC on May 5, 2016)

OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 2 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT FEBRUARY 5, 2016 (Filed With SEC on May 5, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on May 5, 2016)

OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT FEBRUARY 2, 2016 (Filed With SEC on May 5, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on May 5, 2016)

OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT FEBRUARY 2, 2016 (Filed With SEC on May 5, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on May 5, 2016)

OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT FEBRUARY 26, 2016 (Filed With SEC on May 5, 2016)

SEPARATION AGREEMENT BY AND BETWEEN OREXIGEN THERAPEUTICS, INC. AND TAKEDAPHARMACEUTICAL COMPANY LIMITED DATED MARCH 15, 2016 (Filed With SEC on May 5, 2016)

OREXIGEN THERAPEUTICS, INC. Performance Stock Unit Award Agreement (Filed With SEC on May 5, 2016)

OREXIGEN THERAPEUTICS, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee and Collateral Agent INDENTURE Dated as ofMarch 21, 2016 0% Convertible Senior Secured Notes due 2020... (Filed With SEC on March 25, 2016)

SECURITY AGREEMENT among OREXIGENTHERAPEUTICS, INC., as Issuer, and THE GUARANTORSPARTY HERETO FROM TIME TO TIME, as Guarantors and U.S. BANK NATIONALASSOCIATION, as Collateral... (Filed With SEC on March 25, 2016)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on March 15, 2016)

INVESTOR RIGHTSAGREEMENT BY AND AMONG OREXIGEN THERAPEUTICS, INC., BAUPOST GROUP SECURITIES, L.L.C., AND THE OTHERINVESTORS PARTY HERETO DATED AS OF MARCH 15, 2016 TABLE OF... (Filed With SEC on March 15, 2016)

OREXIGEN THERAPEUTICS, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee and Collateral Agent INDENTURE Dated as of March[], 2016 0% Convertible Senior Secured Notes due 2020... (Filed With SEC on March 15, 2016)

FORM OF WARRANT (Filed With SEC on March 15, 2016)

[FORM OF FACE OF NOTE] [INCLUDEFOLLOWING LEGEND IF A GLOBAL NOTE] (Filed With SEC on March 15, 2016)

SECURITY AGREEMENT among OREXIGENTHERAPEUTICS, INC., as Issuer, and THE GUARANTORSPARTY HERETO FROM TIME TO TIME, as Guarantors and U.S. BANK NATIONALASSOCIATION, as Collateral... (Filed With SEC on March 15, 2016)

AMENDED AND RESTATED COLLABORATION AGREEMENT BY AND BETWEEN OREXIGEN THERAPEUTICS, INC. AND TAKEDAPHARMACEUTICAL COMPANY LIMITED DATED July 31, 2015 (Filed With SEC on November 9, 2015)

OREXIGENTHERAPEUTICS, INC. CONSULTING AGREEMENT (Filed With SEC on November 9, 2015)

THIRD AMENDMENT TO LEASE (Filed With SEC on November 9, 2015)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on September 10, 2015)

AMENDEDAND RESTATED NALTREXONE HYDROCHLORIDE SUPPLY AGREEMENT (Filed With SEC on August 7, 2015)

OREXIGENTHERAPEUTICS, INC. CONSULTING AGREEMENT (Filed With SEC on August 7, 2015)

EXHIBIT A OPTION GRANTS (Filed With SEC on June 26, 2015)

AMENDMENT NO. 2 TO MANUFACTURING SERVICES AGREEMENT SEPTEMBER 11, 2014 (Filed With SEC on February 27, 2015)

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THEOMITTED MATERIAL HAS BEEN FILED SEPARATELY... (Filed With SEC on November 10, 2014)

OREXIGEN THERAPEUTICS, INC. Recoupment Policy Acknowledgement (Filed With SEC on April 25, 2014)

NALTREXONE HYDROCHLORIDE SUPPLY AGREEMENT (Filed With SEC on March 13, 2014)

AMENDMENT NUMBER 1 TO COLLABORATION AGREEMENT (Filed With SEC on March 13, 2014)

AMENDMENT NO. 1 TO MANUFACTURING SERVICES AGREEMENT NOVEMBER 1, 2013 (Filed With SEC on March 13, 2014)

OREXIGEN THERAPEUTICS, INC. AS ISSUER 2.75% CONVERTIBLE SENIORNOTES DUE 2020 INDENTURE DATED AS OF DECEMBER 6,2013 WILMINGTON TRUST, NATIONAL ASSOCIATION AS TRUSTEE TABLE OF... (Filed With SEC on December 9, 2013)

OREXIGEN THERAPEUTICS, INC. INDEPENDENT DIRECTOR COMPENSATION POLICY (AS AMENDED AND RESTATED EFFECTIVE AUGUST 27, 2013) (Filed With SEC on November 12, 2013)

EXHIBIT A AMENDMENT TO OREXIGEN THERAPEUTICS, INC. 2007 EQUITY INCENTIVEAWARD PLAN (Filed With SEC on September 23, 2013)

OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 4 TO AMENDED AND RESTATEDEMPLOYMENT AGREEMENT FEBRUARY 15, 2013 (Filed With SEC on August 7, 2013)

OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 1 TO AMENDED AND RESTATEDEMPLOYMENT AGREEMENT FEBRUARY 15, 2013 (Filed With SEC on August 7, 2013)

OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 1 TO SECOND AMENDED ANDRESTATED EMPLOYMENT AGREEMENT FEBRUARY 15, 2013 (Filed With SEC on August 7, 2013)

SECOND AMENDMENT TO LEASE (Filed With SEC on May 9, 2013)

OREXIGEN THERAPEUTICS, INC. INDEPENDENT DIRECTOR COMPENSATION POLICY (AS AMENDED AND RESTATED EFFECTIVE NOVEMBER 29, 2012) (Filed With SEC on March 14, 2013)

11,000,000 Shares OREXIGEN THERAPEUTICS, INC. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT (Filed With SEC on October 25, 2012)

PARTIAL LEASE TERMINATION AGREEMENT (Torrey Pines Court, SanDiego, California) (Filed With SEC on May 10, 2012)

OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 3 TO AMENDED AND RESTATEDEMPLOYMENT AGREEMENT MARCH 15, 2012 (Filed With SEC on March 16, 2012)

OREXIGEN THERAPEUTICS, INC. (a Delaware corporation) 5,646,173 Units Each Unit Consisting of One Share of Common Stock And A Warrant to Purchase Ten Shares of Common Stock... (Filed With SEC on December 15, 2011)

OREXIGEN THERAPEUTICS, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on December 15, 2011)

OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 2 TO AMENDED AND RESTATEDEMPLOYMENT AGREEMENT NOVEMBER 1, 2011 (Filed With SEC on November 3, 2011)

OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 2 TO AMENDED AND RESTATEDEMPLOYMENT AGREEMENT NOVEMBER 1, 2011 (Filed With SEC on November 1, 2011)

AMENDMENT NO. 3 to the LICENSE AGREEMENT dated as of March 31, 2004 (as amended prior to the date hereof) (Filed With SEC on August 8, 2011)

SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on June 14, 2011)

OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 1 TO AMENDED ANDRESTATED EMPLOYMENT AGREEMENT JUNE , 2011 (Filed With SEC on June 14, 2011)

AMENDED AND RESTATED LICENSE AGREEMENT (Filed With SEC on March 11, 2011)

OREXIGEN THERAPEUTICS, INC. KEY EXECUTIVE EMPLOYEE RETENTION BONUS PLAN APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS ON MARCH 2, 2011 (Filed With SEC on March 7, 2011)

EXHIBIT A SEPARATION DATE REAFFIRMATION (To be signed on or within 21 days after the Separation Date.) (Filed With SEC on February 17, 2011)

COLLABORATION AGREEMENT BY AND BETWEEN OREXIGEN THERAPEUTICS, INC. AND TAKEDA PHARMACEUTICAL COMPANY LIMITED DATED SEPTEMBER 1, 2010 TABLE OFCONTENTS (Filed With SEC on November 4, 2010)

AMENDMENTNO. 1 TO LICENSE AGREEMENT (Filed With SEC on November 4, 2010)

AMENDED AND RESTATED MASTER AGREEMENT FOR PHARMACEUTICAL DEVELOPMENT SERVICES (Filed With SEC on May 10, 2010)

Manufacturing Services Agreement March 12, 2010 Table of Contents (Filed With SEC on May 10, 2010)

BUPROPION HYDROCHLORIDE SUPPLY AGREEMENT (Filed With SEC on March 11, 2010)

OREXIGEN THERAPEUTICS, INC. INDEPENDENT DIRECTORCOMPENSATION POLICY (Filed With SEC on March 2, 2010)

OREXIGEN THERAPEUTICS, INC. 2007 EQUITY INCENTIVEAWARD PLAN ARTICLE 1 PURPOSE (Filed With SEC on March 2, 2010)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on January 28, 2010)

EMPLOYMENT AGREEMENT (Filed With SEC on January 28, 2010)

OREXIGEN THERAPEUTICS, INC. 2007 EQUITY INCENTIVEAWARD PLAN ARTICLE 1 PURPOSE (Filed With SEC on November 24, 2009)

OREXIGEN THERAPEUTICS, INC. AMENDMENT NO. 1 TOAMENDED AND RESTATED EMPLOYMENT AGREEMENT OCTOBER 30, 2009 (Filed With SEC on November 4, 2009)

LICENSE AGREEMENT (Filed With SEC on August 7, 2009)

OREXIGEN THERAPEUTICS, INC. (a Delaware corporation) 10,000,000 Shares of Common Stock (Filed With SEC on July 27, 2009)

EMPLOYMENT AGREEMENT (Filed With SEC on April 1, 2009)

EMPLOYMENT AGREEMENT (Filed With SEC on March 13, 2009)

[Remainder of This Page Intentionally Left Blank] (Filed With SEC on March 13, 2009)

RESIGNATION AGREEMENT (Filed With SEC on December 5, 2008)

FIRST AMENDMENT TO LEASE (Filed With SEC on November 7, 2008)

EMPLOYMENT AGREEMENT (Filed With SEC on March 27, 2008)

OREXIGEN THERAPEUTICS, INC. (a Delaware corporation) 7,000,000 Shares of Common Stock PURCHASE AGREEMENT (Filed With SEC on January 24, 2008)

Product Candidate (Filed With SEC on January 14, 2008)

Exhibit No (Filed With SEC on January 7, 2008)

Entry into a Material Definitive Agreement (Filed With SEC on December 14, 2007)

Number of Shares (Filed With SEC on November 8, 2007)

Exhibit No (Filed With SEC on September 18, 2007)

Exhibit No (Filed With SEC on August 28, 2007)

Exhibit No (Filed With SEC on July 3, 2007)

Exhibit No (Filed With SEC on June 20, 2007)

On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on April 9, 2007)

On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on February 16, 2007)

On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on January 23, 2007)

On an intent-to-treat basis, which includes all randomized patients who recorded at least one post-baseline body weight measurement, Contrave demonstrated mean weight loss of 4.0%... (Filed With SEC on December 19, 2006)

Category

Industry

Companies

Contracts

Orexigen Therapeutics, Inc. Contracts & Agreements